Maternal and fetal complications associating lupus anticoagulant and its management; three case reports

Makar, Amin; Vanderheyden, J.S.; Verheyen, A.

doi:10.1016/0028-2243(90)90066-a

European Journal of Obstetrics & Gynecology and Reproductiv

1990

DOI: 10.1016/0028-2243(90)90066-a

|View full text |Cite

Maternal and fetal complications associating lupus anticoagulant and its management; three case reports

Amin Makar

J.S. Vanderheyden

A. Verheyen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

2009

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiphospholipid antibodies (aPLs) are generally described in autoimmunity pathologies such as lupoid sclerosis (1) and systemic lupus erythematosus (2). Over the last fifteen years, the aPLs have been associated with Antiphospholipid Syndrome (APS), typically characterized by arterial and venous thrombosis and recurrent pregnancy loss (3)(4)(5)(6). APS can occur as a primary disorder or may be secondary to connective tissue disease, i.e.…”

mentioning

confidence: 99%

Antiphospholipid Antibodies in Patients with Cancer

Pugliese¹,

Bernardini²,

Pacifico³

et al. 2006

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Antiphospholipid antibodies are generally associated with Antiphospholipid Syndrome, which can occur as a primary disorder or may be secondary to connective tissue disease or tumour. The presence of antiphospholipid antibodies in patients with tumour disease is responsible for thrombotic complications. In a population of 53 tumor patients with positive carcinoembryonic antigen CEA, carbohydrate antigen CA19.9, CA125 and CA15.3 markers, IgM and IgG anticardiolipin and antiphosphatidylinositol were detected by solid-phase immunoassays. Our results show that moderate or high levels of antiphospholipid antibodies are present in a great number of patients with CEA and CA19.9 markers, suggesting a specific association with gastroenteric tumors. By testing for antiphosphatidylinositol antibodies, many patients not evidenced by the standard anticardiolipin assay were found to be antiphospholipid-positive. The analysis of antiphosphatidylinositol antibodies as a diagnostic tool in gastroenteric cancer to highlight patients with the risk of thromboembolic complications is discussed.

show abstract

mentioning

confidence: 99%

Antiphospholipid Antibodies in Patients with Cancer

Pugliese¹,

Bernardini²,

Pacifico³

et al. 2006

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients

Gómez-Puerta

Cervera

Espinosa

et al. 2006

Seminars in Arthritis and Rheumatism

124

View full text Add to dashboard Cite

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy

Zuckerman

Toubi²,

Golan³

et al. 1995

Br J Cancer

106

View full text Add to dashboard Cite

Summary This study was undertaken to determine the prevalence of anti-cardiolipin antibodies (ACLAs) in patients with malignancy and to investigate a possible association of ACLAs with thromboembolic events in such patients. The study included 216 patients with solid and non-solid malignancies and an age-matched control group of 88 healthy subjects. ACLA levels were measured and related to thromboembolic phenomena (diagnosed by imaging methods) that occurred within 12 months of the diagnosis of cancer. Forty-seven patients (approximately 22%) with cancer were ACLA positive as compared with only three subjects (approximately 3%) in the control group (P<0.0001). The ACLA-positive cancer patients had a significantly higher rate of thromboembolic events than ACLA-negative cancer patients: 13 of 47 (28%) vs 24 of 169 (14%), respectively (P<0.05). High titres of either IgG-ACLA or IgM-ACLA were found in 10 out of 13 ACLA-positive cancer patients with thrombotic complications, but in only 2 out of 34 cancer ACLA-positive patients without thromboembolic events (P<0.0001). In four cancer patients in whom ACLA levels were followed ACLA decreased after successful surgery/chemotherapy treatment and remained negative and thromboembolic free for 12 months of follow-up. Patients with malignancies show an increased prevalence of ACLA. Furthermore, ACLA-positive patients, mainly those with high titres, are much more prone to thromboembolic events.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Maternal and fetal complications associating lupus anticoagulant and its management; three case reports

Cited by 5 publications

References 18 publications

Antiphospholipid Antibodies in Patients with Cancer

Antiphospholipid Antibodies in Patients with Cancer

Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy

Contact Info

Product

Resources

About